Skip to content

ُEfficacy of Insulin Versus Hyalase Hydro-dissection of Median Nerve in Rheumatoid Arthritis Patients

Treatment of Carpal Tunnel in Rheumatoid Arthritis

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03394131
Enrollment
90
Registered
2018-01-09
Start date
2017-07-01
Completion date
2018-08-01
Last updated
2018-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment Resistant Carpal Tunnel in RA Patients

Brief summary

Carpal tunnel syndrome (CTS) is a common peripheral entrapment neuropathy in Rheumatoid arthritis patients proved by nerve conduction studies and ultrasound parameters, this study aims to evaluate the effect of hydro-dissection using insulin versus hyalase versus saline, ultrasounic guided as an effective treatment

Detailed description

Carpal tunnel syndrome (CTS) is a common peripheral entrapment neuropathy in Rheumatoid arthritis patients proved by nerve conduction studies and ultrasound parameters, this study aims to evaluate the effect of hydro-dissection of median nerve inside CT twice injections with interval 2 weeks using insulin and 10 cc saline versus hyalase and 10 cc saline versus 10 cc saline, ultrasounic guided as an effective treatment of CT

Interventions

DRUGHylase

hydro-dissection injection of median nerve inside carpal tunnel using hyalase and 10 cc saline

DRUGInsulin

hydro-dissection injection of median nerve inside carpal tunnel using 10 IU insulin and 10 cc saline

OTHERsaline

hydro-dissection injection of median nerve inside carpal tunnel using 10 cc saline

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Rheumatoid arthritis in remission

Exclusion criteria

* active Rheumatoid arthritis

Design outcomes

Primary

MeasureTime frameDescription
pain intensity6 monthsVisual analog scale 0-100

Secondary

MeasureTime frameDescription
nerve conduction6 monthssensory velocity
ultrasound6 monthscross sectional area

Countries

Egypt

Contacts

Primary ContactManal Hassanien, MD
manal_hassanien@yahoo.com01062679200
Backup ContactAbdelraheem Elawamy, MD
arawamyyy@yahoo.com01000032655

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026